Page 40 - Robert Kramer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Executives defend quality control at troubled COVID-19 vaccine plant Emily Kopp © Provided by Roll Call Rep. Mariannette Miller-Meeks (R-IA) listens as Robert Kramer, President and Chief Executive Officer of Emergent BioSolutions, speaks via videoconference during the hearing on the company's handling of COVID-19 vaccines. Executives at a vaccine contractor responsible for contaminating millions of vaccine doses defended its manufacturing quality Wednesday, even as new revelations emerged about the company’s lapses in sanitation, the role of a top Trump administration off...

They are potentially contaminated and may need to be discarded. The New York Times reported last month that the facility may have jeopardized 62 million of J&J's COVID-19 vaccine doses. Emergent BioSolutions CEO Robert G. Kramer admitted to the House of Representatives on Wednesday that more than 100 million doses of the Johnson & Johnson vaccine are on hold and possibly contaminated. It was the first time that Kramer admitted the high figure of potentially spoiled vaccines after The New York Times reported last month that the facility may have jeopardized 62 million of Johnson & Johnson's ...

Pool / Getty Images As Emergent BioSolution's Baltimore factory was throwing away unfinished COVID-19 vaccine doses and struggling to pass muster with the Food and Drug Administration, the company awarded at least $3 million in bonuses to a handful of executives, according to documents released by a congressional subcommittee Wednesday. The House Select Subcommittee on the Coronavirus Crisis grilled executives from Emergent, which was awarded a $628 million contract with the federal government to boost COVID-19 vaccine manufacturing capacity. The subcommittee released a trove of document...

Emergent BioSolutions Inc told U.S. regulators it aims as soon as July to correct the problems at its manufacturing facility that ruined millions of COVID-19…

J&J vaccine production could restart in U.S. 'within days,' Emergent executive testifies POLITICO 5 hrs ago By Sarah Owermohle © Stefani Reynolds/The New York Times via AP, Pool Robert Kramer, president and CEO of Emergent BioSolutions, speaks via videoconference during a hearing on Capitol Hill. Emergent BioSolutions could resume manufacturing Johnson & Johnson's Covid-19 vaccine within days, CEO Robert Kramer told a House panel Wednesday. The Food and Drug Administration ordered Emergent to pause production last month after a series of manufacturing problems at its Balt...